We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Urinary Method Detects Toxin Exposure from Harmful Algal Blooms

By LabMedica International staff writers
Posted on 29 Jan 2020
Print article
Image: The Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Photo courtesy of Thermo Fisher Scientific).
Image: The Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Photo courtesy of Thermo Fisher Scientific).
During harmful algal blooms (HABs), species of cyanobacteria release toxic peptides, including microcystins and nodularin into waterways, impacting wildlife and humans living in these marine environments.

Human exposure comes from ingestion, direct skin contact, or inhalation and can lead to a variety of symptoms ranging from gastroenteritis, nausea, allergic reactions and skin rashes to hepatic injury and hemorrhage in more severe cases. Microcystins also have been linked to tumor progression and are harmful to renal, immune and reproductive systems.

A group of scientists led by the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) tested a newly developed immunocapture protein phosphatase inhibition assay (IC-PPIA) method for detection of microcystins and nodularin in human urine. This method uses a commercially available antibody to specifically isolate microcystins and nodularine from human urine prior to measurement. Urines from the Florida residents were self-collected by participants into sterile collection cups and stored at −80 °C until shipment to the Florida Atlantic University laboratory (Ft. Pierce, FL, USA).

The team used the Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) to measure peak areas from the samples. The highly toxic MC congener microcystin-LR was resolved on an Agilent 1290 liquid chromatograph (Agilent Technologies, Santa Clara, CA, USA) using an Acquity UPLC BEH C18 column (Waters, Milford, MA, USA). A Protein Phosphatase Inhibition Assay was performed and the absorbance was read at 405 nm on a Powerwave HT microplate spectrophotometer (BioTek, Winooski, VT, USA).

The scientists demonstrated that the IC-PPIA method developed by the CDC was able to detect low-dose human exposures to microcystins by analysis of urine from three of the 86 urine specimens analyzed by this new method, which yielded positive results with concentrations of 0.055, 0.089 and 0.052 ng/mL MC-LR equivalents. These findings are the first to report microcystin concentrations directly from exposed residents impacted by cyanobacteria in Florida.

The authors concluded that they had described the development and application of an IC-PPIA for detection of nearly all microcystins (MCs) and nodularin (NOD) in human urine. Ten-fold sample concentration in this method makes it sensitive enough to detect even low-level human inhalation exposures to MCs and NOD. This method could complement water monitoring programs by identifying human exposures to MCs and NOD at the time of HABs and may assist in elucidating health effects associated with these toxins in the future. The study was published on December 19, 2019 in the journal Toxins.

Related Links:
Centers for Disease Control and Prevention
Florida Atlantic University
Thermo Fisher Scientific
Agilent Technologies
BioTek
Waters


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.